STAT+: Eli Lilly’s Zepbound combined with amylin drug led to significant weight loss in mid-stage trial

An investigational combination therapy from Eli Lilly led to significant weight loss in a mid-stage study, but high rates of people stopping the treatment may raise questions about its tolerability. Lilly, which is racing to bring next-generation…

Read the full story at STAT ↗